



Fate Therapeutics

Guiding cells to improve life

ABOUT FATE THERAPEUTICS

Fate Therapeutics is an innovative biotechnology company developing novel stem cell modulators (SCMs), biologic or small molecule compounds that guide cell fate, to treat patients with very few therapeutic options. Fate Therapeutics' lead clinical program, ProHema, consists of pharmacologically-enhanced hematopoietic stem cells (HSCs) designed to improve HSC support during the normal course of a stem cell transplant for the treatment of patients with hematologic malignancies. The Company is also advancing a robust pipeline of human recombinant proteins, each with novel mechanisms of action, for skeletal muscle, beta-islet cell, and post-ischemic tissue regeneration. Fate Therapeutics also applies its award-winning, proprietary induced pluripotent stem cell (iPSC) technology to offer a highly efficient platform to recapitulate human physiology for commercial scale drug discovery and therapeutic use. Fate Therapeutics is headquartered in San Diego, CA, with a subsidiary in Ottawa, Canada.

LEADERSHIP IN STEM CELL BIOLOGY

The modulation of endogenous populations of stem and progenitor cells can be achieved in a cell-type and context-specific manner. Founded in 2007, Fate Therapeutics united six of the leading academic investigators in stem cell and developmental biology to discover and develop conventional pharmaceuticals that selectively target and coax adult stem cells within the body to proliferate and differentiate. The Company has established a robust stem cell biology discovery platform that can be leveraged across a broad therapeutic spectrum of drug discovery and development opportunities to address diseases that currently have limited to no treatment options.

- **Models of Stem Cell Biology and Physiology** – Fate Therapeutics has created powerful phenotypic assays and *in vivo* model systems to elucidate the biology and role of adult stem cell modulation in human physiology and disease.
- **Innovative Cell State Characterization Technologies** – The Company has deployed the most advanced quantitative molecular biology systems, including genomic, proteomic and epigenetic expression technologies, to exquisitely identify and characterize cell state and uncover cell-specific biological mechanisms to modulate cell fate.
- **Award Winning iPSC Technology** – Fate Therapeutics utilizes industry-leading cellular reprogramming and differentiation technologies for generating cell types of interest for target discovery and high-throughput screening. The Company has partnered with Becton Dickinson to commercialize a reprogramming platform that utilizes novel small molecule conditions and offers highly efficient methods to recapitulate human physiology for commercial scale drug discovery.

MANAGEMENT

William Rastetter, Ph.D.

Chairman & Interim CEO

Pratik Multani, M.D., M.S.

SVP, Clinical Development

Dan Shoemaker, Ph.D.

Chief Technology Officer

Scott Wolchko

Chief Financial Officer & VP,
Operations

Peter Flynn, Ph.D.

VP, Biologic Therapeutics

Scott Thies, Ph.D.

Sr. Dir., Stem Cell Biology

INVESTORS

Fate Therapeutics has completed two rounds of private financing and is backed by top-tier life sciences venture investors and a syndicate of strategic investors.

\$15mm Series A

April 2008

\$35mm Series B

November 2009





SCIENTIFIC FOUNDERS

Philip Beachy, Ph.D.

Stanford University

Sheng Ding, Ph.D.

Gladstone Institute of
Cardiovascular Disease

Rudolf Jaenisch, M.D.

Whitehead/Massachusetts
Institute of Technology

Randall Moon, Ph.D.

University of Washington

Michael Rudnicki, Ph.D.

Ottawa Hospital Research Institute

David Scadden, M.D.

Harvard Stem Cell Institute
Massachusetts General Hospital

Leonard Zon, M.D.

Harvard Medical School
Children's Hospital Boston

BOARD OF DIRECTORS

William Rastetter, Ph.D.

Chairman & Interim CEO

John Mendlein, Ph.D.

Board Member

Amir Nashat, Ph.D.

Polaris Venture Partners

Robert Nelsen

ARCH Venture Partners

Bryan Roberts, Ph.D.

Venrock

Carl Weissman

OVP Venture Partners

CONTACT

Fate Therapeutics, Inc.
3535 General Atomics Court
Suite 200
San Diego, CA 92121
858.875.1800
www.fatetherapeutics.com

PROGRAMS

PROHEMA: ProHema is a first-in-class therapeutic consisting of pharmacologically-enhanced hematopoietic stem cells (HSC), where the pharmacologic modulation imparts greater than 20-fold up-regulation of key biological factors for enhanced HSC homing and proliferation. Fate Therapeutics has completed a Phase 1b clinical study for ProHema in hematologic malignancy patients undergoing HSC transplant, and is exploring the therapeutic benefits of ProHema in other settings of HSC transplantation. The Company has submitted to the FDA a clinical protocol to evaluate ProHema in a single-cord blood allogeneic transplant setting.

FT101: Cardiovascular disease is the leading cause of death in the U.S. Each year, about 1.5 million people have a heart attack, of which one third die as a result. Current treatments are time-sensitive and preventative, aimed at reducing injury to the cardiac tissue. However, once injury occurs, no treatments are approved to regenerate cardiac tissue and restore function, leaving patients at risk for subsequent heart attacks and congestive heart failure. Fate is developing FT101, a novel first-in-class biologic that has shown in various preclinical models the potential to regenerate damaged cardiac muscle to restore heart function. Fate has completed characterization and optimization of the protein and is conducting additional pharmacology studies in preparation for clinical development.

FT201: In patients with type 1 diabetes, the number or function of insulin-producing beta cells in the pancreas is dramatically reduced, and patients must be on lifelong daily insulin or other therapeutic interventions to manage blood glucose levels. The regeneration of beta cell number and function represents a potential cure for diabetes. Fate is developing FT201, a biologic that can regenerate islet beta cells in the pancreas to restore insulin production and achieve normal management of blood glucose.

FT301: Muscle wasting disorders afflict more than 28 million, which includes elderly (sarcopenia) and cancer patients (cachexia). Sarcopenia is increasingly recognized as a definable disease in need of treatment and attention. The National Institute on Aging cited sarcopenia as its major concern for the next decade. Orthopedic injury-induced muscle wasting is an important and unaddressed medical need. Patients often have localized muscle wasting that can affect their recovery times and necessitate additional therapy. Fate is developing FT301, a biologic that can induce skeletal muscle growth to support restoration of strength.



Fate Therapeutics has received numerous awards and recognitions for the Company's innovative approach to stem cell medicines.